What Does It Mean to Experience Workplace Burnout as an Oncologist?

News
Video

Workplace burnout in medicine and oncology can lead to stress, exhaustion, fatigue, and a lack of interest in work, according to Eric P. Winer, MD.

Results from a recent survey published in the Journal of Clinical Oncology found that oncologists are experiencing higher rates of burnout in 2023 than they were in 2013.1 In 2013, the rate of burnout was 45%, whereas in 2023, it was 59% (P < .01), a 14% difference. Additionally, more than 20% of oncologists said they were likely to, or definitely would, reduce their hours in the next 12 months.

In the wake of this report, CancerNetwork® spoke with Eric P. Winer, MD, the director of Yale Cancer Center, president and physician in chief at Smilow Cancer Hospital, deputy dean for cancer research and Alfred Gilman Professor of Pharmacology and Professor of Medicine at Yale School of Medicine, chair of the association board for the American Society of Clinical Oncology, and one of the authors on the survey, about the prevalence and effect of oncologist burnout.

Though workplace burnout is a common problem, Winer iterated that when it comes to medicine and oncology, burnout can lead to things such as fatigue, depersonalization, stress, emotional exhaustion, and a lack of empathy toward patients. All these effects of burnout, ultimately, can lead to an “increasingly negative” attitude toward work.

However, Winer also spoke about how there is less burnout in oncology than some people may suspect. He attributes this to the mission-driven nature of the work he does and how the work many oncologists do is meaningful.

Transcript:

Workplace burnout is something that is not unique to the medical profession, and there’s a [lot of] literature on burnout in a variety of different situations. When we talk about burnout related to medicine and related to oncology, we’re talking about a syndrome that involves fatigue, some element of depersonalization, a lack of interest in continuing to pursue work, feeling stressed, feeling emotionally exhausted, and oftentimes feeling a lack of empathy for the people one takes care of, with increasingly negative attitudes about work in general.

People could suspect that oncology would be an area where there would be a lot of burnout. For a lot of oncologists, there’s less burnout, and what keeps many of us from being burned out is the mission-driven nature of the work. I don’t have to go home and worry about whether I gave enough to the world today. There are professions where people don’t have that luxury, and the work I do feels very meaningful.

Reference

Schenkel C, Levit LA, Kirkwood K, et al. State of professional well-being, satisfaction, and career plans among US oncologists in 2023. J Clin Oncol. Published online January 29, 2025. doi:10.1200/OA.24.00010

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content